

# Agile Therapeutics Second Quarter 2022 Earnings Call

August 11, 2022

# Forward-Looking Statements

Certain information contained in this presentation and other matters discussed today or answers that may be given in response to questions may include “forward-looking statements.” We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding our ongoing and planned manufacturing and commercialization of Twirla®, the potential market acceptance and uptake of Twirla®, including the increasing demand for Twirla, our partnership with Afaxys and its ability to promote growth, our product supply agreement with Nurx and its ability to educate patients about Twirla, our connected TV (CTV) campaign and its ability to promote growth, our future plans with respect to our debt financing from Perceptive Advisors, our prospects for future financing arrangements, and our operating expenses, financial condition, growth and strategies. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability to maintain regulatory approval of Twirla and the labeling under any approval we obtain, the ability of Corium to produce commercial supply in quantities and quality sufficient to satisfy market demand for Twirla, our ability to successfully enhance the commercialization of and increase the uptake for Twirla, the size and growth of the markets for Twirla and our ability to serve those markets, regulatory and legislative developments in the United States and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla and our product candidates, the effects of the ongoing COVID-19 pandemic on our commercialization efforts, clinical trials, supply chain, operations of third parties we rely on for services such as manufacturing, marketing support and sales support, as well as on our potential customer base, our ability to maintain compliance with the listing requirements of the Nasdaq Capital Market, and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. These factors could cause actual results and developments to be materially different from those expressed in or implied by such statements. These forward-looking statements are made only as of the date of this presentation and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.


# Q2 2022 & Recent Accomplishments

**1. Increased Twirla Demand and Revenue**

**2. Reduced Quarterly Operating Expenses (OPEX)**

**3. Raised Additional Capital**

# Accelerated Demand (Cycles) and Reduced OPEX



Cycles Dispensed Reflects All Channels as Reported by Symphony Metys.

# Cash Position & Outlook



[ABOUT US](#) [OUR PRODUCT](#) [RESEARCH](#) [INVESTORS](#) [CAREERS](#) [CONTACT](#)

## PRESS RELEASE DETAILS

### AGILE THERAPEUTICS ANNOUNCES CLOSING OF \$24 MILLION UPSIZED PUBLIC OFFERING

July 6, 2022

[PDF Version](#)

# Twirla Initiatives Designed to Advance Growth



afaxys<sup>®</sup>  
affordable access<sup>®</sup>

Did{ |v\$duqhwkls



Twirla<sup>®</sup>  
(levonorgestrel and ethinyl estradiol)  
transdermal system  
Learn more at [Twirla.com](http://Twirla.com)

Wz lrd#WY# rp p hufdo

**New Announcement!**




NURX.

Qxu{#Surgxfw#xssq#Djuhphqw

*Nurx is Thirty Madison's Reproductive Health Brand*

# Momentum in Both Retail and Non-Retail Channels



Prescription data contained herein is from Symphony Health Solutions. Similar data is available from other sources. Cycles = number of 3-patch packages dispensed; Retail = total prescriptions dispensed through retail channels; Non-retail = clinics, hospitals, and other entities dispensing prescriptions direct to patient

# New Twirla Product Supply Agreement with Nurx, Thirty Madison's Reproductive Health Brand

NURX.



# Q&A

# Closing Remarks